Garvinci

Garvinci is a clinical-stage biotechnology company dedicated to developing innovative adeno-associated virus (AAV) gene therapies for central nervous system (CNS) and rare genetic disorders. Founded by pioneers in the field of gene therapy, the company utilizes a proprietary platform for AAV capsid discovery and engineering to improve delivery efficiency and reduce immunogenicity. Their lead program, GVC-001, is an AAV-based gene therapy targeting the GBA1 gene for the treatment of Gaucher disease and GBA-associated Parkinson's disease. The company's pipeline also includes candidates for neurodegenerative conditions such as Amyotrophic Lateral Sclerosis (ALS). Garvinci operates with a global footprint, maintaining research and development facilities in both China and the United States. By integrating cutting-edge science with robust manufacturing capabilities, Garvinci aims to provide life-changing treatments for patients with limited therapeutic options.